Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Depreciation & Amortization (CF) (2023 - 2025)

Immunome (IMNM) has disclosed Depreciation & Amortization (CF) for 3 consecutive years, with $663000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation & Amortization (CF) rose 37.27% year-over-year to $663000.0, compared with a TTM value of $2.5 million through Dec 2025, up 56.25%, and an annual FY2025 reading of $2.5 million, up 56.25% over the prior year.
  • Depreciation & Amortization (CF) was $663000.0 for Q4 2025 at Immunome, up from $589000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $663000.0 in Q4 2025 and bottomed at $94000.0 in Q1 2023.
  • Average Depreciation & Amortization (CF) over 3 years is $379750.0, with a median of $447000.0 recorded in 2024.
  • The sharpest move saw Depreciation & Amortization (CF) skyrocketed 443.56% in 2024, then grew 16.03% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $151000.0 in 2023, then skyrocketed by 219.87% to $483000.0 in 2024, then skyrocketed by 37.27% to $663000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for IMNM at $663000.0 in Q4 2025, $589000.0 in Q3 2025, and $637000.0 in Q2 2025.